|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Breuer EK and Murph MM: The role of
proteomics in the diagnosis and treatment of women's cancers:
Current trends in technology and future opportunities. Int J
Proteomics. 2011:pii: 373584. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Doench JG and Sharp PA: Specificity of
microRNA target selection in translational repression. Genes Dev.
18:504–511. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Meyer SU, Thirion C, Polesskaya A,
Bauersachs S, Kaiser S, Krause S and Pfaffl MW: TNF-α and IGF1
modify the microRNA signature in skeletal muscle cell
differentiation. Cell Commun Signal. 13:42015. View Article : Google Scholar
|
|
7
|
Tian L, Fang YX, Xue JL and Chen JZ: Four
microRNAs promote prostate cell proliferation with regulation of
PTEN and its downstream signals in vitro. PLoS One. 8:e758852013.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ambros V: MicroRNA pathways in flies and
worms: Growth, death, fat, stress, and timing. Cell. 113:673–676.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Calin GA, Sevignani C, Dumitru CD, Hyslop
T, Noch E, Yendamuri S, Shimizu M, Rattan S, Bullrich F, Negrini M,
et al: Human microRNA genes are frequently located at fragile sites
and genomic regions involved in cancers. Proc Natl Acad Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Farazi TA, Hoell JI, Morozov P and Tuschl
T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lages E, Ipas H, Guttin A, Nesr H, Berger
F and Issartel JP: MicroRNAs: Molecular features and role in
cancer. Front Biosci (Landmark Ed). 17:2508–2540. 2012. View Article : Google Scholar
|
|
12
|
Bray I, Bryan K, Prenter S, Buckley PG,
Foley NH, Murphy DM, Alcock L, Mestdagh P, Vandesompele J, Speleman
F, et al: Widespread dysregulation of miRNAs by MYCN amplification
and chromosomal imbalances in neuroblastoma: Association of miRNA
expression with survival. PLoS One. 4:e78502009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhao X, Zhao Z, Xu W, Hou J and Du X:
Down-regulation of miR-497 is associated with poor prognosis in
renal cancer. Int J Clin Exp Pathol. 8:758–764. 2015.PubMed/NCBI
|
|
14
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa
M, et al: The microRNA expression signature of bladder cancer by
deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu J, Wang T, Cao Z, Huang H, Li J, Liu W,
Liu S, You L, Zhou L, Zhang T, et al: miR-497 downregulation
contributes to the malignancy of pancreatic cancer and associates
with a poor prognosis. Oncotarget. 5:6983–6993. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li NF, Broad S, Lu YJ, Yang JS, Watson R,
Hagemann T, Wilbanks G, Jacobs I, Balkwill F, Dafou D, et al: Human
ovarian surface epithelial cells immortalized with hTERT maintain
functional pRb and p53 expression. Cell Prolif. 40:780–794. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lagos-Quintana M, Rauhut R, Lendeckel W
and Tuschl T: Identification of novel genes coding for small
expressed RNAs. Science. 294:853–858. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu H, Li W, Chen C, Pei Y and Long X:
miR-335 acts as a potential tumor suppressor miRNA via
downregulating ROCK1 expression in hepatocellular carcinoma. Tumour
Biol. 36:6313–6319. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tu Y, Liu L, Zhao D, Liu Y, Ma X, Fan Y,
Wan L, Huang T, Cheng Z and Shen B: Overexpression of miRNA-497
inhibits tumor angiogenesis by targeting VEGFR2. Sci Rep.
5:138272015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bailey-Wilson JE, Amos CI, Pinney SM,
Petersen GM, de Andrade M, Wiest JS, Fain P, Schwartz AG, You M,
Franklin W, et al: A major lung cancer susceptibility locus maps to
chromosome 6q23–25. Am J Hum Genet. 75:460–474. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Girard L, Zöchbauer-Müller S, Virmani AK,
Gazdar AF and Minna JD: Genome-wide allelotyping of lung cancer
identifies new regions of allelic loss, differences between small
cell lung cancer and non-small cell lung cancer, and loci
clustering. Cancer Res. 60:4894–4906. 2000.PubMed/NCBI
|
|
22
|
Guo ST, Jiang CC, Wang GP, Li YP, Wang CY,
Guo XY, Yang RH, Feng Y, Wang FH, Tseng HY, et al: MicroRNA-497
targets insulin-like growth factor 1 receptor and has a tumour
suppressive role in human colorectal cancer. Oncogene.
32:1910–1920. 2013. View Article : Google Scholar :
|
|
23
|
Li D, Zhao Y, Liu C, Chen X, Qi Y, Jiang
Y, Zou C, Zhang X, Liu S, Wang X, et al: Analysis of miR-195 and
miR-497 expression, regulation and role in breast cancer. Clin
Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu JW, Wang TX, You L, Zheng LF, Shu H,
Zhang TP and Zhao YP: Insulin-like growth factor 1 receptor
(IGF-1R) as a target of miR-497 and plasma IGF-1R levels associated
with TNM stage of pancreatic cancer. PLoS One. 9:e928472014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Ruan WD, Wang P, Feng S, Xue Y and Zhang
B: MicroRNA-497 inhibits cell proliferation, migration, and
invasion by targeting AMOT in human osteosarcoma cells. Onco
Targets Ther. 9:303–313. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Luo M, Shen D, Zhou X, Chen X and Wang W:
MicroRNA-497 is a potential prognostic marker in human cervical
cancer and functions as a tumor suppressor by targeting the
insulin-like growth factor 1 receptor. Surgery. 153:836–847. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xu S, Fu G-B, Tao Z, OuYang J, Kong F,
Jiang BH, Wan X and Chen K: miR-497 decreases cisplatin resistance
in ovarian cancer cells by targeting mTOR/P70S6K1. Oncotarget.
6:26457–26471. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eccles MR, He S, Legge M, Kumar R, Fox J,
Zhou C, French M and Tsai RW: PAX genes in development and disease:
The role of PAX2 in urogenital tract development. Int J Dev Biol.
46:535–544. 2002.PubMed/NCBI
|
|
29
|
Robson EJ, He SJ and Eccles MR: A PANorama
of PAX genes in cancer and development. Nat Rev Cancer. 6:52–62.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Luu VD, Boysen G, Struckmann K, Casagrande
S, von Teichman A, Wild PJ, Sulser T, Schraml P and Moch H: Loss of
VHL and hypoxia provokes PAX2 up-regulation in clear cell renal
cell carcinoma. Clin Cancer Res. 15:3297–3304. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chan-Ling T, Chu Y, Baxter L, Weible Ii M
and Hughes S: In vivo characterization of astrocyte precursor cells
(APCs) and astrocytes in developing rat retinae: Differentiation,
proliferation, and apoptosis. Glia. 57:39–53. 2009. View Article : Google Scholar
|
|
32
|
Sims-Lucas S, Cusack B, Baust J,
Eswarakumar VP, Masatoshi H, Takeuchi A and Bates CM: Fgfr1 and the
IIIc isoform of Fgfr2 play critical roles in the metanephric
mesenchyme mediating early inductive events in kidney development.
Dev Dyn. 240:240–249. 2011. View Article : Google Scholar :
|
|
33
|
Li CG and Eccles MR: PAX genes in cancer;
Friends or foes? Front Genet. 3:62012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Weber S, Taylor JC, Winyard P, Baker KF,
Sullivan-Brown J, Schild R, Knüppel T, Zurowska AM, Caldas-Alfonso
A, Litwin M, et al: SIX2 and BMP4 mutations associate with
anomalous kidney development. J Am Soc Nephrol. 19:891–903. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tong GX, Chiriboga L, Hamele-Bena D and
Borczuk AC: Expression of PAX2 in papillary serous carcinoma of the
ovary: immunohistochemical evidence of fallopian tube or secondary
Müllerian system origin? Mod Pathol. 20:856–863. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Tung CS, Mok SC, Tsang YT, Zu Z, Song H,
Liu J, Deavers MT, Malpica A, Wolf JK, Lu KH, et al: PAX2
expression in low malignant potential ovarian tumors and low-grade
ovarian serous carcinomas. Mod Pathol. 22:1243–1250. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Khoubehi B, Kessling AM, Adshead JM, Smith
GL, Smith RD and Ogden CW: Expression of the developmental and
oncogenic PAX2 gene in human prostate cancer. J Urol.
165:2115–2120. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Silberstein GB, Dressler GR and Van Horn
K: Expression of the PAX2 oncogene in human breast cancer and its
role in progesterone-dependent mammary growth. Oncogene.
21:1009–1016. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Gnarra JR and Dressler GR: Expression of
Pax-2 in human renal cell carcinoma and growth inhibition by
antisense oligonucleotides. Cancer Res. 55:4092–4098.
1995.PubMed/NCBI
|
|
40
|
Muratovska A, Zhou C, He S, Goodyer P and
Eccles MR: Paired-box genes are frequently expressed in cancer and
often required for cancer cell survival. Oncogene. 22:7989–7997.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Buttiglieri S, Deregibus MC, Bravo S,
Cassoni P, Chiarle R, Bussolati B and Camussi G: Role of Pax2 in
apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma
cells. J Biol Chem. 279:4136–4143. 2004. View Article : Google Scholar
|
